Home

CHANE GRAZIANO

CIK 1133234 · Chief Executive Officer · last filed 2013-11-07

CHANE GRAZIANO is a Chief Executive Officer who has filed 14 SEC Form 4 insider transactions across 2 companies since 2007. The most recent filing, for HBIO, was dated Nov 7, 2013. Across all open-market trades the lifetime net is +$494.7K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.4M across reported positions. 35 SEC filings were submitted jointly with HARVARD BIOSCIENCE INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.41M

Companies

2

Total Filings

14

Lifetime Open-Market Net

$494.7K

Filer Profile

Reported Address
C/O HARVARD BIOSCIENCEINC
84 OCTOBER HILL ROAD
HOLLISTON, MA 01746-1371
Related Filers
HARVARD BIOSCIENCE INC — 35 joint filings, latest 2019-05-13
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
HBIO Chief Executive Officer 300,515 $8.03 $2.41M $494.7K 13 2013-11-07
Harvard Apparatus Regenerative Technology, Inc. (HART) Delisted 10%+ Owner 676,287 $30.67 $20.74M $0 1 2013-11-07

Recent Filings

14 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2013-11-07 HBIO Gift (G) −100,000 $0 EDGAR
2013-11-07 Harvard Apparatus Regenerative Technology, Inc. (HART) Delisted Gift (G) −100,000 $0 EDGAR
2013-08-29 HBIO Buy (P) +60,000 $300.0K EDGAR
2013-07-31 HBIO Mixed +437,707 -$359.0K EDGAR
2012-12-13 HBIO Exer (M) +200,000 $696.0K EDGAR
2012-06-04 HBIO Grant (A) +105,042 $0 EDGAR
2011-06-07 HBIO Grant (A) +53,750 $0 EDGAR
2011-01-26 HBIO Tax (F) −11,353 -$46.3K EDGAR
2010-09-16 HBIO Buy (P) +100,000 $358.1K EDGAR
2010-09-16 HBIO Buy (P) −44,732 -$163.3K EDGAR
Showing 1–10 of 14
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.